Requires drug labels to show where ingredients and finished products were originally made.
This bill would make drug labels include detailed information about where their active ingredients and finished products were originally manufactured. This means everyday Americans would get more transparency about their medicines. Drug companies would need to update their labels and tracking systems to provide this new information, either directly on the label or through an online link.
Today, drug labels must show the name and location of the manufacturer, packer, or distributor. After this bill, labels for finished drug products and active pharmaceutical ingredients would also need to include the name, location, and a unique identifier for the original manufacturer of the product and its active ingredients, or a link to an electronic portal with this information. Finished drug products that are marked in accordance with the requirements of section 502(b)(2)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)(2)(A)) would also be exempt from separate customs country of origin marking requirements.
S 3788 · 119th Congress · February 5, 2026 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
22 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.